# Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

> **NCT03548155** · NA · COMPLETED · sponsor: **Tianjin Anding Hospital** · enrollment: 65 (actual)

## Conditions studied

- Schizophrenia
- Therapeutics

## Interventions

- **DRUG:** Berberine
- **DRUG:** atypical antipsychotic
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03548155
- **Lead sponsor:** Tianjin Anding Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-24
- **Primary completion:** 2015-12-14
- **Final completion:** 2017-05-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548155, "Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03548155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*